Cybin Partners With Osmind To Accelerate Commercial Preparation For Its Clinical-Stage Psychiatry Programs

Cybin Inc., a clinical-stage neuropsychiatry company, is partnering with Osmind, which advances psychiatry through technology services. Through this partnership, Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for Cybin’s clinical-stage pipeline.

Cybin seeks to create an operational infrastructure, to include a clinical workflow that includes pharmacy, fulfillment, consumer access, and reimbursement for two of its compounds involved in clinical testing. The compounds are:

CYB003, which is in Phase 3 development as adjunct treatment for major depressive disorder.

CYB004, which is in a Phase 2 . . .